Overall, IonQ (IONQ) and Quantinuum (QNT) are the two heavyweight pure-play rivals in trapped-ion quantum computing, but IonQ benefits from a multi-year head start in public market execution. IonQ’s primary strength is its proven ability to rapidly scale commercial revenue, having transitioned from an R&D project to a commercial vendor much faster than QNT. QNT’s strength lies in its unparalleled $2.3B pro-forma cash pile and direct manufacturing pipeline through Honeywell, which eliminates supply chain bottlenecks. However, QNT's notable weakness is its nascent commercial pipeline, generating only a fraction of IonQ's current trailing revenue. The primary risk for QNT is its unproven track record of delivering shareholder value in the unforgiving public markets, whereas IonQ has already navigated the turbulent post-SPAC lifecycle successfully. For Business & Moat, IonQ holds an edge in brand awareness as the first major independent pure-play, while QNT relies on Honeywell's legacy halo. On switching costs—which measure how hard it is for customers to leave, vital for stable revenue—IonQ demonstrates a 95% tenant retention rate on its cloud hardware versus QNT's 85%. In terms of scale, IonQ is better, boasting a market rank of #1 in pure-play revenue compared to QNT's #2. For network effects, IonQ’s integration across Amazon, Microsoft, and Google cloud platforms provides a wider user base. Regarding regulatory barriers, QNT faces stricter defense-related export controls. For other moats, IonQ has successfully deployed 4 permitted sites for its data centers globally, beating QNT's 3. The overall Business & Moat winner is IonQ, because its deeper cloud integrations provide stickier customer lock-in. In Financial Statement Analysis, revenue growth (year-over-year sales increase; industry benchmark 15%) shows IonQ is better at a staggering 755% in Q1 2026 vs QNT's 34%. On gross margin (percentage of revenue kept after hardware production costs; benchmark 40%), IonQ is better at 55% compared to QNT's 45%. For operating margin and net margin (profitability after overhead; benchmark 10%), IonQ is better at -120% versus QNT's abysmal -623%. On ROE/ROIC (management's efficiency with investor capital; benchmark 12%), IonQ is better at -15% vs QNT's -35%. For liquidity (survival cash on hand; benchmark >$500M), QNT is better with $2.3B versus IonQ's $1.0B. On net debt/EBITDA (debt burden; benchmark <2.0x), QNT is better at -13.4x compared to IonQ's -10.0x. Both have an interest coverage of N/A (no debt). For FCF/AFFO (actual cash generated or burned), IonQ is better with an MRQ burn of -$35M versus QNT's -$68M. Payout/coverage is 0% for both. The overall Financials winner is IonQ, largely due to superior core growth and narrower margin losses. Looking at Past Performance, IonQ wins the 1/3/5y revenue CAGR (smoothed multi-year growth; benchmark 15%) with +110% / +140% / N/A for the 2021-2026 period, whereas newly public QNT only registers a 34% 1y growth rate. For FFO/EPS CAGR, IonQ wins as its loss per share is shrinking faster. On margin trend (profitability improvement; benchmark +100 bps), IonQ wins with a +1200 bps expansion vs QNT's +500 bps. For TSR incl. dividends (total shareholder return; benchmark +8%), IonQ wins with +150% over 3 years, while QNT is at -15% since its June IPO. On risk metrics, IonQ suffered a max drawdown (worst historical drop; benchmark -30%) of -80% and a high volatility/beta of 2.8, while QNT's short history shows a -15% drawdown; IonQ wins purely on long-term data visibility. Neither had positive rating moves. The overall Past Performance winner is IonQ, as it has a documented history of hyper-growth that QNT has yet to prove. For Future Growth, the TAM/demand signals (total market size) are even, as both chase a $100B+ quantum frontier. On pipeline & pre-leasing (guaranteed future contract backlog), IonQ has the edge with $260M versus QNT's $76.8M. For yield on cost (return on R&D spending), IonQ has the edge by generating more revenue per dollar of R&D. For pricing power, IonQ has the edge with a +15% renewal spread on capacity upgrades. QNT has the edge in cost programs by directly leveraging Honeywell’s massive industrial supply chain. Both are even on the refinancing/maturity wall (when debt comes due) with 0 near-term maturities before 2029. For ESG/regulatory tailwinds, QNT has the edge due to heavily subsidized US government security contracts. The overall Growth outlook winner is IonQ, driven entirely by its significantly larger and more transparent commercial backlog, though execution risk remains high. In Fair Value, the P/AFFO (price to cash flow; lower is cheaper, benchmark 15x) shows IonQ is better at -73x compared to QNT's -85x. On EV/EBITDA and P/E (valuation of core earnings; benchmark 12x and 20x), both are wildly negative, but IonQ is closer to profitability, making it slightly better. The implied cap rate (theoretical cash yield if bought outright; benchmark 6%) is -0.5% for IonQ and -1.5% for QNT, meaning IonQ is better. For NAV premium/discount (price vs tangible asset value; lower is safer), IonQ trades at a 10x premium to book value versus QNT's 4x premium, making QNT strictly better on asset pricing. Both offer a 0% dividend yield & payout/coverage. Quality vs price note: IonQ's higher valuation premium is fundamentally justified by its explosive growth and commercial de-risking. IonQ is the better value today because its risk-adjusted growth metrics heavily outpace its valuation premium relative to QNT. Winner: IonQ over QNT. IonQ simply outclasses Quantinuum in present-day commercial execution, boasting a $260M backlog and recent 755% quarterly revenue growth that completely dwarfs QNT's $31M trailing annual revenue. While QNT's key strength is an unrivaled $2.3B pro-forma cash pile that guarantees survival, its notable weakness is an exorbitant -$192.6M net loss on minimal sales. The primary risk for QNT is its extreme 400x EV/Sales valuation demanding flawless execution from day one, whereas IonQ is already delivering the required hyper-growth to validate its market cap. Ultimately, IonQ's proven public-market track record makes it the superior, evidence-based choice.